Discovery of new protein that triggers breast cancer
Researchers at the University of Exeter have found that a walk of just fifteen minutes can reduce chocolate cravings. The benefits of exercise in helping people manage dependencies on nicotine and other drugs have previously been recognised. Now, for the first time, newly-published research shows that the same may be true for food cravings. Following
Full Post: Fifteen minute walk can reduce food cravings
Canadian researchers have identified a new protein in the progression of breast cancer.
According to a recent study from the Université de Montréal and the University of Alberta, published in the Journal of Biological Chemistry, the protein ARF1 plays a critical role in cancer cell growth and the spread of tumours. Targeting this protein with drug therapy may provide hope to women with breast cancer.
“Until now, ARF1 has been associated with harmless albeit important housekeeping duties of cells,” says senior author Audrey Claing, a professor of pharmacology at the Université de Montréal. “The Université de Montréal and the University of Alberta team is the first to characterize the role of ARF1 in breast cancer.”
Dr. Claing and her colleagues used invasive breast cancer cell lines to study ARF1’s role. These cells are sensitive to a particular growth factor, called epidermal growth factor or EGF, which has previously been shown to stimulate tumour growth and invasion. Their findings suggest that EGF works through ARF1 in these cells. In addition, when ARF1 activity was chemically blocked, breast cancer cell migration and growth was reduced. Conversely, when ARF1 was overproduced in these cells, their movement was enhanced.
“Taken together our findings reveal an unsuspected role for ARF1 and indicate that this small protein may be a potential therapeutic target for the treatment of invasive breast cancers,” says Dr. Claing, who is a member of the Groupe d’étude des protéines membranaires as well a the Groupe de Recherche Universitaire sur le Médicament, two multidisciplinary research teams dedicated to the study of membrane protein functions and the identification of new therapeutic targets for drug discovery.
In an important finding published online in Developmental Cell, researchers at Albert Einstein College of Medicine of Yeshiva University, along with collaborators at Massachusetts Institute of Technology, have identified a protein likely responsible for causing breast cancer to spread. Metastatic cancer occurs when cancer cells from the original tumor travel to distant sites via the
Full Post: Discovery of protein that may cause breast cancer to spread
If scientists knew exactly what a breast cancer cell needs to spread, then they could stop the most deadly part of the disease: metastasis. New research from the University of North Carolina at Chapel Hill School of Medicine takes a step in that direction. Carol Otey, Ph.D. and UNC colleagues reduced the ability of breast
Full Post: Palladin may play important role in metastasis of breast cancer cells
A discovery by Canada-U.S. biophysicists will improve the understanding of ion channels, akin to little ‘nano-machines’ or ‘nano-valves’ in our body, which when they malfunction can cause genetic illnesses that attack muscles, the central nervous system and the heart. As reported in the current issue of the Proceedings of the National Academy of Sciences (
Full Post: New understanding of ion channels in the body
Metastasis is the ability of cancer cells to spread from a primary site, to form tumours at distant sites. It is a complex process in which cell motility and invasion play a fundamental role. Essential to our understanding of how metastasis develops is identification of the molecules, and characterisation of the mechanisms that regulate cell
Full Post: Exciting cancer discovery
A new study reveals that the metadherin gene (MTDH) plays a role in both cancer metastasis and resistance to chemotherapy. The research, published by Cell Press in the January 6th issue of the journal Cancer Cell , identifies MTDH as a promising therapeutic target for high risk breast cancers. “Most breast cancer patients resist currently
Full Post: Metadherin gene plays dual role in breast cancers with poor prognosis